Albany, NewYork (PRWEB) August 17, 2013
The Acute Myeloid Leukemia Insight report is designed for clients needing a quality in-depth understanding of the dynamics and structure of the Acute Myeloid Leukemia report. These reports provide a much more granular and detailed data set than our competitors. All data have been researched, brand upwards, by an experienced ''on-the-ground'' industry analyst who conducts face-to-face interviews with key producers, leading companies in allied industries, distributors and retailers.
Acute myeloid (myelogenous, myelocytic) leukemia is a rapidly progressing blood cancer with a poor overall prognosis. AML is relatively rare, and predominantly affects older adults. AML is a heterogeneous disease, and many subtypes have been identified. The current standard of care consists of cytarabine-based chemotherapy, which can often achieve remission. However, the majority of patients relapse, and survival rates are grim. There are clear unmet needs for treatments that can prolong the overall survival of these patients, but drug manufacturers have struggled to gain regulatory approval for new therapies.
This report focuses on the remaining opportunity in AML exclusive of the acute promyleocytic leukemia (APL) subtype.
Overview of AML, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
Topline AML therapeutics market revenue from 2012–2017. Annual cost of therapy, and peak pipeline drug sales of drugs launching during this forecast period are included.
Key topics covered include strategic competitor assessment, market characterization, unmet needs, R&D strategies, and clinical trial design for the AML therapeutics market.
Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline drugs. An interactive clinical and commercial analyzer tool is available.
Analysis of the current and future market competition in the global AML therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons To Buy
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the global AML therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AML therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Browse All GlobalData Market Research Reports @ http://www.researchmoz.us/publisher/globaldata-1.html.
Key Questions Answered
Which AML patients have the greatest unmet needs?
What are the R&D strategies drug makers are pursuing in the AML space?
Why has it been so difficult for Pharma to develop successful therapies for AML?
How are players aiming to circumvent difficulties that have historically plagued AML drug development?
What are the most promising pipeline agents for AML? How do their clinical and commercial attributes compare to one another?
What opportunities will remain following the launch of these pipeline agents?
Do KOLs see a role for targeted therapies and immunotherapies in the treatment of AML?
GlobalData forecasts the AML therapeutics market in the 6MM to grow from $151.0m in 2012 to $430.7m in 2017, at a CAGR of 23.3%. The main driver of growth in the global AML market will be the uptake of premium-priced pipeline agents.
Despite high levels of unmet need, uptake of new drugs will be limited, as KOLs are relatively unimpressed by these agents. Therefore, ample market opportunity will remain at the end of the forecast period.
To circumvent historical difficulties with regulatory approval, companies are designing early- and late-stage clinical trials more rigorously. Randomization of early-stage trials is critical, and the designation of overall survival (OS) as the primary endpoint of pivotal studies is mandatory.
Key R&D trends include developing therapies for the patients with greatest unmet need, particularly the elderly, developing combination therapies, and investigating new targets (i.e. FLT3) involved in the pathogenesis of AML.
Despite the hype around FLT3 inhibitors, KOLs are unconvinced that these drugs will be successful as monotherapies in AML.
1) Orphan Drugs Partnering Terms and Agreements
This report contains(http://www.researchmoz.us/orphan-drugs-partnering-terms-and-agreements-report.html) over 140 links to online copies of actual orphan drugs deals and where available, contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
2) Pain Management Therapeutics Market
The global(http://www.researchmoz.us/pain-management-therapeutics-market-global-industry-size-share-trends-analysis-and-forecast-2012-2018-report.html) pain management therapeutics market is expected to witness a decline during the forecast period (2012 to 2018) due to patent expirations of the key blockbuster revenue generating drugs such as Cymbalta (duloxetine) of Eli Lilly & Co. and Lyrica (pregabalin) of Pfizer, Inc. This report studies the global market for pain management therapeutics from three perspectives - therapeutic classes of drugs, indications and geography. Each of these segments is further classified into sub-segments; therapeutic classes include anticonvulsants, antidepressants, anesthetics, NSAIDs, opioids, anti-migraine agents and other non-narcotic analgesics.
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
For More Information Kindly Contact:
Visit Blog @ http://industryresearchnews.blogspot.com